Imprimis Pharmaceuticals Story Overview

IMMY -- USA Stock  

USD 2.40  0.01  0.42%

Macroaxis does not monitor all media channels or aggregates social signals for Imprimis Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Imprimis Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Imprimis Pharmaceuticals. Please also check Imprimis Pharmaceuticals Hype Analysis, Imprimis Pharmaceuticals Correlation and Imprimis Pharmaceuticals Performance.
Should You Be Concerned About Imprimis Pharmaceuticals Incs Shareholders
Simply Wall StFull coverage

Read More...   

Story Momentum

This media report from simplywall.st distributed on March 8, 2018 was a factor to the next trading day price decrease.The trading delta at closing time against the next closing price was 5.24% . The trading delta at closing time when the story was published against the current closing price is 15.24% .

Similar stores for Imprimis Pharmaceuticals

few days ago at http://utahherald.com 
EPS for Marten Transport, Ltd. Expected At 0.22 Shorts at Imprimis Pharmaceuticals Lowered By 9.42
news
UtahHerald.comMarten Transport, Ltd. - MRTN - Stock Price Today - Zacks ZacksUS Xpress prices IPO at 16share Seeking AlphaFull coverage
over a week ago at http://wolcottdaily.com 
TIER REIT, Inc. Reaches 22.25 52-Week High Imprimis Pharmaceuticals s Sentiment Is 0.88
news
Wolcott DailyFull coverage
over two weeks ago at http://www.thewellesleysnews.com 
Securities Analyst Recommendations International Tower Hill Mines Ltd. , Imprimis Pharmaceuticals, Inc.
news
Analyst JournalFull coverage
over three weeks ago at http://www.journalfinance.net 
Investors Focused Stocks T2 Biosystems, Inc. , USD Partners LP , Imprimis ...
news
Market Breaking Point Full coverage
over a month ago at http://www.reuters.com 
BRIEF-Surface Pharmaceuticals, Inc. Announces 20 Million Series A Financing ...
reuters
IMPRIMIS PHARMACEUTICALS - SURFACE PHARMA INTENDS TO USE PROCEEDS OF FINANCING TO ADVANCE CLINICAL DEVELOPMENT PROGRAMS FOCUSED ON OCULAR SURFACE DISEASE Source text for Eikon Further company coverage ...
over a month ago at http://www.journalfinance.net 
Two sizzlers Stocks are not to be missed Agenus Inc. , GAMCO Global Gold, Natural Reso NYSE ...
news
Market Breaking Point Full coverage
over a month ago at http://bzweekly.com 
Piedmont Investment Advisors Cut Its Holding in Manpowergroup Com by 420966 as Stock Declined As ...
news
BZ WeeklyFull coverage
over a month ago at http://simplywall.st 
What does Imprimis Pharmaceuticals Incs Balance Sheet Tell Us About Its Future
news
Simply Wall StFull coverage
over a month ago at http://bzweekly.com 
Imprimis Pharmaceuticals Holder Marathon Asset Management LP Cut Holding by 645147 Jw Asset ...
news
BZ WeeklyShareholder Bluecrest Capital Management LTD Has Raised Michael Kors Hldgs LTD Position Imprimis ... MoneyMakingArticlesFull coverage
over a month ago at http://normanobserver.com 
Imprimis Pharmaceuticals, Inc. Reaches 2.20 After 3.00 percent Down Move Last Week Mettler-Toledo Internationa...
news
NormanObserver.comFull coverage
over two months ago at http://bzweekly.com 
Imprimis Pharmaceuticals Inc Institutional Investors Quarterly Sentiment
news
BZ WeeklyImprimis Pharmaceuticals Inc Q4 2017 Institutional Investor Sentiment Better Than Expected Frisco FastballFull coverage

Did you try this?

Run Analyst Recommendations Now
   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Analyst Recommendations

Current Liabilities

Current Liabilities Comparative Analysis
  Current Liabilities 
      Imprimis Pharmaceuticals Comparables 
Imprimis Pharmaceuticals is currently under evaluation in current liabilities category among related companies. Current Liabilities is company's short term debts. This usually includes obligations that are due within next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Peers

Imprimis Pharmaceuticals Related Equities
VBIV  8.31 %   
0%
100.0%
DRNA  2.66 %   
0%
32.0%
NK  1.97 %   
0%
23.0%
DNLI  1.65 %   
0%
19.0%
DRRX  1.38 %   
0%
16.0%
DMPI  0.94 %   
0%
11.0%
DMTX  0.00 %   
0%
0%
DOVA  0.13 %   
1.0%
0%
VBLT  3.57 %   
42.0%
0%
VCEL  4.05 %   
48.0%
0%
Please also check Imprimis Pharmaceuticals Hype Analysis, Imprimis Pharmaceuticals Correlation and Imprimis Pharmaceuticals Performance. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.